Focus: Recordati is a mid-cap specialty pharmaceutical company headquartered in France with 1,001-5,000 employees, focused on small molecule manufacturing across oncology, rare diseases, endocrinology, cardiovascular, and hematology. The company operates as a public company with a highly concentrated revenue base centered on its flagship product.
Profile data last refreshed 14h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Recordati to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Recordati's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship revenue driver representing 67% of company revenue; 11β-hydroxylase inhibitor with patent protection extending to 2035 and active Phase 4 trial in mild autonomous cortisol secretion.
Help build intelligence for Recordati
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Rare metabolic disorder treatment with CPS1 activator mechanism; patent cliff approaching 2028, representing second-largest revenue source now at risk.
Methylating agent for rare amino acid metabolism disorder; approaching LOE with no specified expiration date.
Rare ophthalmic indication for cystinosis; cystine-depleting agent with peak lifecycle status and orphan disease positioning.
Somatostatin receptor agonist with imminent patent expiration (December 2026); currently in Phase 2 for prolactin-producing pituitary adenoma expansion.
Biologic classical complement pathway inhibitor (BLA); represents company's entry into monoclonal antibody space with peak lifecycle status.
Lead chelation agent for pediatric environmental poisoning; niche orphan-adjacent indication with minimal revenue.
NSAID for neonatal cardiac indication; legacy product with approaching patent expiration and minimal commercial significance.
Long-acting formulation of pasireotide with reusable ServoPen delivery device; patent cliff by May 2028.
Prostaglandin synthesis inhibitor for neonatal cardiac intervention; peak lifecycle with patent protection through March 2032.
7 discontinued, 5 duplicate formulations not shown
EU greenlights Recordati deal under streamlined merger scrutiny - The Brussels Times
EU greenlights Recordati deal under streamlined merger scrutiny The Brussels Times
EU greenlights Recordati deal under streamlined merger scrutiny - The Brussels Times
EU greenlights Recordati deal under streamlined merger scrutiny The Brussels Times
8-K Filing: IONIS PHARMACEUTICALS INC (IONS) (CIK 0000874015) — 8-K
8-K
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati - Yahoo Finance
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati Yahoo Finance
Ionis grants Recordati rights to zilganersen for Alexander disease - Pharmaceutical Technology
Ionis grants Recordati rights to zilganersen for Alexander disease Pharmaceutical Technology
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati - Zacks Investment Research
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati Zacks Investment Research
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company
Cost-effectiveness of pasireotide long-acting release in acromegaly: a systematic literature review and methodology assessment.
Impact of Osilodrostat on Health-Related Quality of Life in Cushing's Disease: Analysis of Patient-Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials.
+2 more products
Showing 5 of 10 publications